Hormonal
Adropin34-76 treatment activates pyruvate dehydrogenase (PDH) and downregulates PDH kinase-4 (PDK-4) in skeletal muscle, promoting glucose oxidation in obese mice.
This study indicates that obesity can lead to reduced activity of pyruvate dehydrogenase (PDH), a key enzyme for glucose oxidation. Adropin treatment was shown to restore PDH activity, promoting glucose oxidation. This suggests that maintaining healthy enzyme activity is crucial for metabolic health, and future therapies may target these pathways.
Adropin treatment activated pyruvate dehydrogenase (PDH), a rate-limiting enzyme in glucose oxidation, and down-regulated PDH kinase-4 (PDK-4) that inhibits PDH.
Why this rating
Controlled animal study with specific biochemical assays. The findings are robust within the model but are mechanistic details.
Source
Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance
Su Gao et al. · Molecular Metabolism · 2015
DOI 10.1016/j.molmet.2015.01.005
More from this paper
- Administration of the bioactive peptide adropin34-76 improves glucose tolerance and insulin sensitivity in diet-induced obese mice by enhancing skeletal muscle insulin signaling and shifting fuel preference toward glucose oxidation.Moderate
- Adropin34-76 treatment reduces incomplete fatty acid oxidation and increases the CoA/acetyl-CoA ratio in skeletal muscle, indicating improved mitochondrial function in obese mice.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →